BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Biostar Pharmaceuticals, Inc. (BSPM) Says Gelatin Scandal Will Cut Q2 Revenues in Half


8/9/2012 10:58:51 AM

by Richard Daverman, PhD

August 8, 2012 -- Biostar Pharma of Xianyang warned investors that its second quarter was severely hurt by China’s gelatin scandal, which began in April of this year. Because Biostar was ordered to stop all sales of gelatin products, the company’s Q2 revenues will be cut in half from the nearly $16 million it recorded in Q1. Stressing the positive, Biostar reported the Xianyang SFDA gave permission on July 30 to re-start its production of gelatin-based capsules. The company expects Q3 to be much improved, while it hopes Q4 will see revenues return to normal levels. More details....

Stock Symbol: (NSDQ: BSPM)


Read at ChinaBio Today


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->